BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

Release of Contrave data validates FDA's demand for second trial

Orexigen Therapeutics Inc. (NASDAQ:OREX) gained $1.85 (32%) to $7.64 after an interim analysis of the LIGHT cardiovascular (CV) outcomes study showed that the company's obesity drug Contrave naltrexone/bupropion may have a cardiovascular benefit. The data release could compromise the ongoing trial, but FDA had already requested a second trial when it approved Contrave last fall. more >>

   COMPANY NEWS

J&J launches second Bay Area JLABS incubator

Johnson & Johnson (NYSE:JNJ) launched the fourth incubator in its JLABS network, located in South San Francisco, Calif., and named the first 10 companies in residence. J&J said the incubator can accommodate up to 50 startups. more >>

NICE backs Harvoni for some HCV patients

The U.K.'s NICE published draft guidance recommending Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) as a cost-effective treatment for certain subpopulations of patients with HCV genotypes 1 and 4 at a list price of L38,980 ($60,017) for a 12-week course. Comments are due March 23. more >>

Blueprint, Alexion start rare disease collaboration

Blueprint Medicines (Cambridge, Mass.) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) started a research collaboration to develop small molecules against an undisclosed activated kinase that causes a rare genetic disease. more >>

Management tracks

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) named Toru Kimura and Hajime Kinuta executive officers, effective April 1. Kimura is director of Sumitomo's regenerative & cellular medicine office; Kinuta is its director of global corporate planning. more >>

   POLITICS & POLICY

NIGMS readies pilot program for grants

Jon Lorsch, director of the NIH's National Institute of General Medical Sciences (NIGMS), told the U.S. House Appropriations Committee that a new pilot program could make the agency's nearly $2 billion granting process more efficient and introduce a new funding mechanism for early-stage investigators. more >>

Advertisement

BIOCENTURY

BIOCENTURY
User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement